Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:PAPOLG-ABCA12

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: PAPOLG-ABCA12
	FusionPDB ID: 62617
	FusionGDB2.0 ID: 62617
		Hgene	Tgene
	Gene symbol	PAPOLG	ABCA12
	Gene ID	64895	26154
	Gene name	poly(A) polymerase gamma	ATP binding cassette subfamily A member 12
	Synonyms	-	ARCI4A\|ARCI4B\|ICR2B\|LI2
	Cytomap	2p16.1	2q35
	Type of gene	protein-coding	protein-coding
	Description	poly(A) polymerase gammaPAP-gammaSRP RNA 3' adenylating enzyme/pap2SRP RNA 3'-adenylating enzymeSRP RNA-adenylating enzymeneo-PAPneo-poly(A) polymerasenuclear poly(A) polymerase gammapolynucleotide adenylyltransferase gammasignal recognition part	ATP-binding cassette sub-family A member 12ATP-binding cassette transporter 12ATP-binding cassette, sub-family A (ABC1), member 12
	Modification date	20200320	20200313
	UniProtAcc	.	Q86UK0 Main function of 5'-partner protein: FUNCTION: Probable transporter involved in lipid homeostasis.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000238714, ENST00000483370,	ENST00000412081, ENST00000272895, ENST00000389661,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	3 X 3 X 3=27	5 X 6 X 4=120
	# samples	3	5
	** MAII score	log2(3/27*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0	log2(5/120*10)=-1.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: PAPOLG [Title/Abstract] AND ABCA12 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: PAPOLG [Title/Abstract] AND ABCA12 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	PAPOLG(60997646)-ABCA12(215821502), # samples:1
Anticipated loss of major functional domain due to fusion event.	PAPOLG-ABCA12 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PAPOLG-ABCA12 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PAPOLG-ABCA12 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PAPOLG-ABCA12 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	PAPOLG	GO:0043631	RNA polyadenylation	11287430\|11463842
Tgene	ABCA12	GO:0006869	lipid transport	16007253
Tgene	ABCA12	GO:0010875	positive regulation of cholesterol efflux	23931754
Tgene	ABCA12	GO:0072659	protein localization to plasma membrane	23931754

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:60997646/chr2:215821502)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across PAPOLG (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ABCA12 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000238714	PAPOLG	chr2	60997646	-	ENST00000272895	ABCA12	chr2	215821502	-	3504	741	225	2411	728
ENST00000238714	PAPOLG	chr2	60997646	-	ENST00000389661	ABCA12	chr2	215821502	-	2424	741	225	2411	728

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000238714	ENST00000272895	PAPOLG	chr2	60997646	-	ABCA12	chr2	215821502	-	0.000965885	0.99903417
ENST00000238714	ENST00000389661	PAPOLG	chr2	60997646	-	ABCA12	chr2	215821502	-	0.001573684	0.9984263

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PAPOLG-ABCA12

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
PAPOLG	chr2	60997646	ABCA12	chr2	215821502	741	172	FVPVIKFEFDGIEVFYLVPVAFSIGI

Top

Potential FusionNeoAntigen Information of PAPOLG-ABCA12 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

PAPOLG-ABCA12_60997646_215821502.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B50:01	FEFDGIEV	0.9939	0.8849	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:01	FEFDGIEV	0.9883	0.9897	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:01	EFDGIEVF	0.9787	0.9908	7	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B41:01	FEFDGIEV	0.9485	0.9885	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:13	FEFDGIEV	0.9373	0.9944	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:01	FEFDGIEVF	0.9983	0.9893	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B13:01	FEFDGIEVF	0.9969	0.9952	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B47:01	FEFDGIEVF	0.9929	0.8232	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:03	FEFDGIEVF	0.9895	0.9948	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:01	FEFDGIEVF	0.961	0.9866	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:05	FEFDGIEVF	0.9411	0.5759	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:08	EFDGIEVFY	0.9	0.935	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:02	FEFDGIEVF	0.8758	0.9939	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:13	FEFDGIEVF	0.777	0.9846	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B50:02	FEFDGIEVF	0.7676	0.6945	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B38:01	FEFDGIEVF	0.7667	0.9871	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:03	FEFDGIEVF	0.7562	0.9761	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B38:02	FEFDGIEVF	0.7469	0.9913	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:18	FEFDGIEVF	0.7173	0.9647	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:37	FEFDGIEVF	0.6087	0.9228	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:10	FEFDGIEVF	0.6079	0.8718	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B50:01	FEFDGIEVF	0.3793	0.7317	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B41:01	FEFDGIEVF	0.3406	0.982	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B52:01	FEFDGIEVF	0.2697	0.995	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:03	FEFDGIEVFY	0.9981	0.9865	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:01	FEFDGIEVFY	0.9971	0.9844	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B47:01	FEFDGIEVFY	0.9954	0.7599	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B47:01	KFEFDGIEVF	0.9939	0.8044	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-A26:02	EVFYLVPVAF	0.9898	0.6126	12	22
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B13:01	KFEFDGIEVF	0.979	0.9944	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-A26:15	EVFYLVPVAF	0.9728	0.6381	12	22
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-A26:14	EVFYLVPVAF	0.9728	0.6381	12	22
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:03	KFEFDGIEVF	0.9696	0.9941	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-A26:03	EVFYLVPVAF	0.965	0.6444	12	22
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:03	KFEFDGIEVF	0.958	0.9644	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:13	KFEFDGIEVF	0.9094	0.9761	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:01	KFEFDGIEVF	0.8542	0.9859	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B47:01	FEFDGIEVFYL	0.9993	0.7701	6	17
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B13:01	FEFDGIEVFYL	0.9992	0.9872	6	17
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B47:01	IKFEFDGIEVF	0.9987	0.7267	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:03	IKFEFDGIEVF	0.9975	0.7826	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:01	IKFEFDGIEVF	0.9877	0.9835	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:13	FEFDGIEVFYL	0.9595	0.9583	6	17
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B40:06	FEFDGIEV	1	0.7873	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:07	EFDGIEVF	0.9997	0.8433	7	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:10	EFDGIEVF	0.9997	0.8045	7	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:14	EFDGIEVF	0.9903	0.8056	7	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B51:07	FEFDGIEV	0.9568	0.9956	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B40:03	FEFDGIEVF	0.9988	0.578	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B40:06	FEFDGIEVF	0.9984	0.7685	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B51:07	DGIEVFYLV	0.994	0.8875	9	18
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B54:01	EVFYLVPVA	0.9829	0.8358	12	21
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:09	FEFDGIEVF	0.9787	0.5998	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:10	KFEFDGIEV	0.976	0.9399	5	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:07	KFEFDGIEV	0.9758	0.9274	5	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:08	FEFDGIEVF	0.9559	0.503	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:31	FEFDGIEVF	0.9496	0.989	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:05	FEFDGIEVF	0.9289	0.9876	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:10	FEFDGIEVF	0.9133	0.704	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:10	EFDGIEVFY	0.8847	0.6963	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:31	EFDGIEVFY	0.8823	0.967	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:21	FEFDGIEVF	0.881	0.9894	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:07	EFDGIEVFY	0.8657	0.7312	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C07:10	FEFDGIEVF	0.8492	0.9924	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:09	FEFDGIEVF	0.8479	0.6791	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C07:67	FEFDGIEVF	0.829	0.9895	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C07:80	FEFDGIEVF	0.829	0.9895	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:21	EFDGIEVFY	0.7585	0.9781	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:12	FEFDGIEVF	0.7468	0.9876	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:05	FEFDGIEVF	0.7383	0.984	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:08	FEFDGIEVF	0.6494	0.9663	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C12:16	FEFDGIEVF	0.6296	0.9925	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B51:07	FEFDGIEVF	0.1396	0.984	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:14	EFDGIEVFY	0.0895	0.594	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:10	EFDGIEVFYL	0.9994	0.6394	7	17
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:07	EFDGIEVFYL	0.9992	0.6376	7	17
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B40:03	KFEFDGIEVF	0.9983	0.5961	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:07	FEFDGIEVFY	0.9948	0.7431	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:10	FEFDGIEVFY	0.9948	0.762	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B40:03	FEFDGIEVFY	0.9921	0.5436	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B40:06	KFEFDGIEVF	0.9884	0.7591	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:05	FEFDGIEVFY	0.9746	0.9768	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-A26:01	EVFYLVPVAF	0.9728	0.6381	12	22
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:31	FEFDGIEVFY	0.9695	0.9797	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:08	KFEFDGIEVF	0.9574	0.9634	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:09	KFEFDGIEVF	0.9571	0.579	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:21	FEFDGIEVFY	0.9295	0.9836	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:10	KFEFDGIEVF	0.9198	0.7256	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:08	FEFDGIEVFYL	0.9572	0.9183	6	17
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:01	EFDGIEVF	0.9997	0.8433	7	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B40:04	FEFDGIEV	0.9996	0.942	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C18:01	EFDGIEVF	0.9995	0.846	7	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B50:05	FEFDGIEV	0.9939	0.8849	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B50:04	FEFDGIEV	0.9939	0.8849	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:05	FEFDGIEV	0.9883	0.9897	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:03	FEFDGIEV	0.9851	0.9888	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:06	FEFDGIEV	0.9846	0.9907	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:11	EFDGIEVF	0.9813	0.9836	7	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:05	EFDGIEVF	0.9787	0.9908	7	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:03	EFDGIEVF	0.978	0.9898	7	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:11	FEFDGIEV	0.9715	0.9853	6	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:04	FEFDGIEVF	0.9992	0.9906	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:07	FEFDGIEVF	0.9987	0.9785	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:05	FEFDGIEVF	0.9983	0.9893	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:08	FEFDGIEVF	0.9982	0.9788	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-A68:02	DGIEVFYLV	0.9982	0.7746	9	18
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:06	FEFDGIEVF	0.998	0.9909	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:03	FEFDGIEVF	0.998	0.9883	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B40:04	FEFDGIEVF	0.9972	0.8055	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-A68:02	EVFYLVPVA	0.9969	0.9158	12	21
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-A69:01	DGIEVFYLV	0.9945	0.8831	9	18
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B51:09	DGIEVFYLV	0.9938	0.538	9	18
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-A69:01	EVFYLVPVA	0.9936	0.9034	12	21
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:11	FEFDGIEVF	0.9919	0.9867	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:26	FEFDGIEVF	0.9895	0.9948	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:07	FEFDGIEVF	0.9895	0.9948	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:13	FEFDGIEVF	0.9895	0.9948	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:01	KFEFDGIEV	0.9758	0.9274	5	14
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:24	FEFDGIEVF	0.9658	0.9886	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:77	FEFDGIEVF	0.961	0.9866	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:23	FEFDGIEVF	0.9554	0.9874	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:20	FEFDGIEVF	0.9452	0.9937	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:11	FEFDGIEVF	0.9399	0.9846	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:27	FEFDGIEVF	0.9375	0.9938	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:08	FEFDGIEVF	0.9331	0.9824	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:50	FEFDGIEVF	0.93	0.9934	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:20	FEFDGIEVF	0.929	0.9925	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:28	FEFDGIEVF	0.9212	0.9927	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:43	FEFDGIEVF	0.9147	0.9828	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B53:02	FEFDGIEVF	0.8921	0.8255	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:23	EFDGIEVFY	0.8876	0.9689	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:53	FEFDGIEVF	0.8837	0.9886	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:24	FEFDGIEVF	0.8791	0.9915	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:20	EFDGIEVFY	0.8691	0.9816	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:01	EFDGIEVFY	0.8657	0.7312	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B48:02	FEFDGIEVF	0.8354	0.9914	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C12:02	FEFDGIEVF	0.8311	0.9936	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C07:02	FEFDGIEVF	0.829	0.9895	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C18:01	EFDGIEVFY	0.8203	0.7541	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:02	FEFDGIEVF	0.8177	0.986	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:04	EFDGIEVFY	0.8141	0.9853	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C07:17	FEFDGIEVF	0.8109	0.9913	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:31	FEFDGIEVF	0.8101	0.9866	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:12	FEFDGIEVF	0.8026	0.9883	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B38:05	FEFDGIEVF	0.7667	0.9871	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:13	FEFDGIEVF	0.6976	0.9268	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:54	FEFDGIEVF	0.6147	0.9876	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:11	FEFDGIEVF	0.6115	0.9441	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C07:17	EFDGIEVFY	0.5623	0.9857	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B41:03	FEFDGIEVF	0.5084	0.7771	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:68	FEFDGIEVF	0.4957	0.8978	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B50:04	FEFDGIEVF	0.3793	0.7317	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B50:05	FEFDGIEVF	0.3793	0.7317	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:09	FEFDGIEVF	0.1951	0.7448	6	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:04	EFDGIEVFY	0.1233	0.8133	7	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:01	EFDGIEVFYL	0.9992	0.6376	7	17
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C18:01	EFDGIEVFYL	0.999	0.6636	7	17
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:04	FEFDGIEVFY	0.9984	0.9862	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:07	FEFDGIEVFY	0.9982	0.974	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:07	FEFDGIEVFY	0.9981	0.9865	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:13	FEFDGIEVFY	0.9981	0.9865	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:26	FEFDGIEVFY	0.9981	0.9865	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:08	FEFDGIEVFY	0.9973	0.9731	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:05	FEFDGIEVFY	0.9971	0.9844	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:06	FEFDGIEVFY	0.997	0.9862	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:03	FEFDGIEVFY	0.9966	0.9831	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-C04:01	FEFDGIEVFY	0.9948	0.7431	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:11	FEFDGIEVFY	0.9897	0.9762	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B40:04	KFEFDGIEVF	0.9759	0.7978	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:68	KFEFDGIEVF	0.9751	0.8806	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:20	FEFDGIEVFY	0.975	0.985	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-A25:01	EVFYLVPVAF	0.975	0.866	12	22
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:53	KFEFDGIEVF	0.9723	0.9872	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:07	KFEFDGIEVF	0.9696	0.9941	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:26	KFEFDGIEVF	0.9696	0.9941	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B44:13	KFEFDGIEVF	0.9696	0.9941	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:11	KFEFDGIEVF	0.9681	0.9856	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:28	KFEFDGIEVF	0.9676	0.9886	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:28	FEFDGIEVFY	0.9657	0.9849	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B35:20	FEFDGIEVFY	0.9627	0.987	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:54	KFEFDGIEVF	0.9625	0.9845	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:53	FEFDGIEVFY	0.9562	0.9809	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B48:02	KFEFDGIEVF	0.9462	0.9872	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:02	KFEFDGIEVF	0.9362	0.978	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:12	FEFDGIEVFY	0.9341	0.9795	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:54	FEFDGIEVFY	0.9208	0.9778	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:04	KFEFDGIEVF	0.9104	0.9869	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:06	KFEFDGIEVF	0.8858	0.9841	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B48:02	FEFDGIEVFY	0.8744	0.9816	6	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:05	KFEFDGIEVF	0.8542	0.9859	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:08	KFEFDGIEVF	0.8426	0.9141	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B41:03	KFEFDGIEVF	0.8187	0.7551	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:03	KFEFDGIEVF	0.8125	0.9846	5	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B40:04	FEFDGIEVFYL	0.9996	0.7817	6	17
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:68	IKFEFDGIEVF	0.9983	0.6831	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:11	FEFDGIEVFYL	0.9982	0.9784	6	17
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B48:02	IKFEFDGIEVF	0.998	0.9789	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:53	IKFEFDGIEVF	0.998	0.9459	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B15:54	IKFEFDGIEVF	0.9974	0.919	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:11	IKFEFDGIEVF	0.9954	0.9778	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:04	IKFEFDGIEVF	0.9928	0.9866	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:06	IKFEFDGIEVF	0.9904	0.9834	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:08	IKFEFDGIEVF	0.9881	0.9473	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:05	IKFEFDGIEVF	0.9877	0.9835	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:11	KFEFDGIEVFY	0.984	0.9718	5	16
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B18:03	IKFEFDGIEVF	0.9805	0.982	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B39:02	FEFDGIEVFYL	0.9706	0.9621	6	17
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B40:04	IKFEFDGIEVF	0.9664	0.7767	4	15
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	741	HLA-B41:03	FEFDGIEVFYL	0.9554	0.7409	6	17

Top

Potential FusionNeoAntigen Information of PAPOLG-ABCA12 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of PAPOLG-ABCA12

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
2333	FEFDGIEVFYLVPV	PAPOLG	ABCA12	chr2	60997646	chr2	215821502	741

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PAPOLG-ABCA12

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	2333	FEFDGIEVFYLVPV	-6.43585	-7.47235
HLA-B14:02	3BVN	2333	FEFDGIEVFYLVPV	-6.03076	-6.14536
HLA-B52:01	3W39	2333	FEFDGIEVFYLVPV	-6.40521	-6.51981
HLA-B52:01	3W39	2333	FEFDGIEVFYLVPV	-6.31008	-7.34658
HLA-A11:01	4UQ2	2333	FEFDGIEVFYLVPV	-12.7867	-12.9013
HLA-A24:02	5HGA	2333	FEFDGIEVFYLVPV	-8.18289	-8.29749
HLA-A24:02	5HGA	2333	FEFDGIEVFYLVPV	-5.10018	-6.13668
HLA-B27:05	6PYJ	2333	FEFDGIEVFYLVPV	-2.96594	-4.00244
HLA-B44:05	3DX8	2333	FEFDGIEVFYLVPV	-5.5975	-5.7121
HLA-B44:05	3DX8	2333	FEFDGIEVFYLVPV	-4.41143	-5.44793
HLA-A02:01	6TDR	2333	FEFDGIEVFYLVPV	-2.75414	-3.79064

Top

Vaccine Design for the FusionNeoAntigens of PAPOLG-ABCA12

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	12	21	EVFYLVPVA	GAAGTTTTCTACTTGGTGCCTGTAGCG
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	12	22	EVFYLVPVAF	GAAGTTTTCTACTTGGTGCCTGTAGCGTTT
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	4	15	IKFEFDGIEVF	ATAAAATTTGAATTTGATGGTATTGAAGTTTTC
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	5	14	KFEFDGIEV	AAATTTGAATTTGATGGTATTGAAGTT
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	5	15	KFEFDGIEVF	AAATTTGAATTTGATGGTATTGAAGTTTTC
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	5	16	KFEFDGIEVFY	AAATTTGAATTTGATGGTATTGAAGTTTTCTAC
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	6	14	FEFDGIEV	TTTGAATTTGATGGTATTGAAGTT
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	6	15	FEFDGIEVF	TTTGAATTTGATGGTATTGAAGTTTTC
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	6	16	FEFDGIEVFY	TTTGAATTTGATGGTATTGAAGTTTTCTAC
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	6	17	FEFDGIEVFYL	TTTGAATTTGATGGTATTGAAGTTTTCTACTTG
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	7	15	EFDGIEVF	GAATTTGATGGTATTGAAGTTTTC
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	7	16	EFDGIEVFY	GAATTTGATGGTATTGAAGTTTTCTAC
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	7	17	EFDGIEVFYL	GAATTTGATGGTATTGAAGTTTTCTACTTG
PAPOLG-ABCA12	chr2	60997646	chr2	215821502	9	18	DGIEVFYLV	GATGGTATTGAAGTTTTCTACTTGGTG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of PAPOLG-ABCA12

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
PRAD	PAPOLG-ABCA12	chr2	60997646	ENST00000238714	chr2	215821502	ENST00000272895	TCGA-EJ-7784-01A

Top

Potential target of CAR-T therapy development for PAPOLG-ABCA12

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

ABCA12

chr2:60997646

chr2:215821502

ENST00000272895

2072_2092

2596.0

Transmembrane

Helical

Tgene

ABCA12

chr2:60997646

chr2:215821502

ENST00000272895

2103_2123

2596.0

Transmembrane

Helical

Tgene

ABCA12

chr2:60997646

chr2:215821502

ENST00000272895

2187_2207

2596.0

Transmembrane

Helical

Tgene

ABCA12

chr2:60997646

chr2:215821502

ENST00000272895

2270_2290

2596.0

Transmembrane

Helical

Tgene

ABCA12

chr2:60997646

chr2:215821502

ENST00000389661

1747_1767

2278.0

Transmembrane

Helical

Tgene

ABCA12

chr2:60997646

chr2:215821502

ENST00000389661

1979_1999

2278.0

Transmembrane

Helical

Tgene

ABCA12

chr2:60997646

chr2:215821502

ENST00000389661

2035_2055

2278.0

Transmembrane

Helical

Tgene

ABCA12

chr2:60997646

chr2:215821502

ENST00000389661

2072_2092

2278.0

Transmembrane

Helical

Tgene

ABCA12

chr2:60997646

chr2:215821502

ENST00000389661

2103_2123

2278.0

Transmembrane

Helical

Tgene

ABCA12

chr2:60997646

chr2:215821502

ENST00000389661

2187_2207

2278.0

Transmembrane

Helical

Tgene

ABCA12

chr2:60997646

chr2:215821502

ENST00000389661

2270_2290

2278.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to PAPOLG-ABCA12

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to PAPOLG-ABCA12

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)